IZABRIGHT-Breast01
IZABRIGHT-Breast01 is the global first-line trial of the EGFR×HER3 bispecific ADC in triple-negative breast cancer.
Directly competes with the populations of ASCENT-03 and TROPION-Breast02.
Setting
First-line metastatic TNBC ineligible for PD-(L)1 inhibitors: iza-bren vs chemotherapy
Phase
Phase 3
Sponsor
BMS
Registry
Enrolled
570
Replication
Ongoing; no results.